Showing results (61-70 of 79) with videos related to

Sort By:
Pageof 8
Gynecologic Oncology|May 31, 2022
Synergistic activity of neratinib in combination with olaparib in uterine serous carcinoma overexpressing HER2/neuGhanshyam Yadav, Dana M Roque, Stefania Bellone, et al.
Gynecologic Oncology|August 23, 2019
PARP-1 activity (PAR) determines the sensitivity of cervical cancer to olaparibAnna Bianchi, Salvatore Lopez, Gary Altwerger, et al.
Gynecologic Oncology|July 15, 2017
Superior in vitro and in vivo activity of trastuzumab-emtansine (T-DM1) in comparison to trastuzumab, pertuzumab and their combination in epithelial ovarian carcinoma with high HER2/neu expressionGulden Menderes, Elena Bonazzoli, Stefania Bellone, et al.
British Journal of Cancer|February 12, 2022
Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancerDana M Roque, Eric R Siegel, Natalia Buza, et al.
Gynecologic Oncology|January 12, 2019
PI3K oncogenic mutations mediate resistance to afatinib in HER2/neu overexpressing gynecological cancersElena Bonazzoli, Emiliano Cocco, Salvatore Lopez, et al.
Gynecologic Oncology|August 28, 2021
DHES0815A, a novel antibody-drug conjugate targeting HER2/neu, is highly active against uterine serous carcinomas in vitro and in vivoJoan Tymon-Rosario, Elena Bonazzoli, Stefania Bellone, et al.
Gynecologic Oncology|May 22, 2022
Homologous recombination deficiency (HRD) signature-3 in ovarian and uterine carcinosarcomas correlates with preclinical sensitivity to Olaparib, a poly (adenosine diphosphate [ADP]- ribose) polymerase (PARP) inhibitorJoan R Tymon-Rosario, Paola Manara, Diego D Manavella, et al.
Gynecologic Oncology|December 17, 2019
In vitro and in vivo activity of sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (Trop-2) in uterine serous carcinomaChanhee Han, Emanuele Perrone, Burak Zeybek, et al.
Oncotarget|February 22, 2020
Preclinical activity of sacituzumab govitecan (IMMU-132) in uterine and ovarian carcinosarcomasSalvatore Lopez, Emanuele Perrone, Stefania Bellone, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 27, 2018
Inhibition of BET Bromodomain Proteins with GS-5829 and GS-626510 in Uterine Serous Carcinoma, a Biologically Aggressive Variant of Endometrial CancerElena Bonazzoli, Federica Predolini, Emiliano Cocco, et al.
Pageof 8